Jia Liu, Translational Lead, Early Phase Drug Development at The Kinghorn Cancer Centre, shared a post on LinkedIn:
“Honoured to co-chair and speak in the inaugural Tumour-Agnostic Track educational session at ESMO25 Congress today – alongside track chair Vivek Subbiah, MD, my co-chair Juliana Rodrigues Beal, and speakers Niamh Coleman and Albrecht Stenzinger.
I discussed the landscape of tumour-agnostic immunotherapy and antibody drug conjugates, but are they ready for prime time…?
We explored the critical need for innovative trial designs, biomarker harmonisation, and, importantly, regulatory alignment – all essential to overcome real-world implementation barriers and deliver these life-extending therapies to patients with rare cancers who are still waiting.
Deeply grateful to Caitlin Delaney for allowing me to share her story on the global stage to advocate for progress in tumour-agnostic drug development.
There is much work to be done!”
Follow the latest ESMO 2025 news on OncoDaily.
